Scholarlink

<p>Cladribine tablets (CladT) for relapsing multiple sclerosis help reset the immune system with short treatment courses over 2&#xa0;years. This analysis of MAGNIFY-MS contrasted clinical outcomes with changes in immune cells, proteins and genes over 2&#xa0;years in 270 participants. Most immune cells decreased 3&#xa0;months after starting CladT. Gradual recovery was seen in naïve, regulatory, and transitional B cells starting at month (M)3 and M6. Gene activity related to immune response changes was also reported. Fewer cells producing pro-inflammatory signals and more cells producing anti-inflammatory signals were detected by M24. Immunoglobulin levels mostly remained normal, and a marker of neuroaxonal damage (serum neurofilament light chain) was decreased. Significant reductions in lesion count occurred from M2 onwards. Annualised relapse rate was 0.11 (95% confidence interval: 0.09, 0.15). Over 90% of participants were free of 6-month confirmed disability progression, around 87% had no confirmed progression on 9-hole peg test and timed 25-foot walk. No significant correlations were seen between clinical parameters and lymphocyte dynamics. The safety profile was consistent with previous studies. These findings provide evidence of CladT rebalancing the immune system towards a more homeostatic and less pathogenic state.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月4日

查看全文
  • Heinz Wiendl,
  • Frederik Barkhof,
  • Xavier Montalban,
  • Anat Achiron,
  • Tobias Derfuss,
  • Andrew Chan,
  • Suzanne Hodgkinson,
  • Alexandre Prat,
  • Letizia Leocani,
  • Klaus Schmierer,
  • Finn Sellebjerg,
  • Patrick Vermersch,
  • Hulin Jin,
  • Anita Chudecka,
  • Andreas Kloetgen,
  • Dongdong Lin,
  • Lidia Gardner,
  • Nicola De Stefano

摘要

Cladribine tablets (CladT) for relapsing multiple sclerosis help reset the immune system with short treatment courses over 2 years. This analysis of MAGNIFY-MS contrasted clinical outcomes with changes in immune cells, proteins and genes over 2 years in 270 participants. Most immune cells decreased 3 months after starting CladT. Gradual recovery was seen in naïve, regulatory, and transitional B cells starting at month (M)3 and M6. Gene activity related to immune response changes was also reported. Fewer cells producing pro-inflammatory signals and more cells producing anti-inflammatory signals were detected by M24. Immunoglobulin levels mostly remained normal, and a marker of neuroaxonal damage (serum neurofilament light chain) was decreased. Significant reductions in lesion count occurred from M2 onwards. Annualised relapse rate was 0.11 (95% confidence interval: 0.09, 0.15). Over 90% of participants were free of 6-month confirmed disability progression, around 87% had no confirmed progression on 9-hole peg test and timed 25-foot walk. No significant correlations were seen between clinical parameters and lymphocyte dynamics. The safety profile was consistent with previous studies. These findings provide evidence of CladT rebalancing the immune system towards a more homeostatic and less pathogenic state.